1
|
Ucuncu Kefeli A, Yaprak Bayrak B, Betul Tunce E, Vural C, Suyusal IH, Kefeli U, Aksu MG. Expression of netrin-1 in uterine serous carcinoma and its association with prognosis. Int J Gynaecol Obstet 2024; 166:1337-1344. [PMID: 38588254 DOI: 10.1002/ijgo.15513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 03/13/2024] [Accepted: 03/18/2024] [Indexed: 04/10/2024]
Abstract
BACKGROUND/OBJECTIVES At present, there are few biomarkers used to predict the prognosis of uterine serous carcinoma (USC). Netrin-1 may be a promising biomarker candidate. We investigated netrin-1 expression in USC tissues and healthy endometrial tissues to determine its relevance to disease prognosis. MATERIALS AND METHODS Netrin-1 expression was examined in the tissues of 48 patients with USC and 30 patients with healthy benign endometrial tissues via immunohistochemistry. RESULTS None of the healthy tissues were stained with netrin-1. In tumor tissues, the overall positivity rate of netrin-1 was 75%, detected as high expression in 17 patients (35%) and low in 19 (40%). Patients who had tumors with no netrin-1 expression (n = 12) had a median overall survival (OS) of 60.0 months (95% confidence interval [CI], 47-98), whereas patients who had tumors with low to strong netrin-1 expression (n = 33) had a lower median OS of 50 months, but the difference was not statistically significant (95% CI, 58-108; P = 0.531). Disease-free survival (DFS) was not statistically significant between the groups (95% CI, 67.7-115.9; P = 0.566). Patients with a tumor diameter ≥2 cm had higher netrin-1 expression than those with a tumor diameter of 2 cm (P = 0.027). We did not find any difference in overall and DFS when age, tumor stage, histology, tumor diameter, p53 status, lymphovascular space invasion, myometrial invasion, and lymph node metastasis were compared according to netrin-1 expression (P > 0.05). CONCLUSION Netrin-1 was expressed in USC but not in healthy tissues. Its expression was not associated with OS or DFS.
Collapse
Affiliation(s)
- Aysegul Ucuncu Kefeli
- Faculty of Medicine, Department of Radiation Oncology, Kocaeli University, Kocaeli, Turkey
| | - Busra Yaprak Bayrak
- Faculty of Medicine, Department of Pathology, Kocaeli University, Kocaeli, Turkey
| | - Esra Betul Tunce
- Faculty of Medicine, Department of Pathology, Kocaeli University, Kocaeli, Turkey
| | - Cigdem Vural
- Faculty of Medicine, Department of Pathology, Kocaeli University, Kocaeli, Turkey
| | - Ibrahim Halil Suyusal
- Faculty of Medicine, Department of Radiation Oncology, Kocaeli University, Kocaeli, Turkey
| | - Umut Kefeli
- Division of Medical Oncology, Faculty of Medicine, Department of Internal Medicine, Kocaeli University, Kocaeli, Turkey
| | - Maksut Gorkem Aksu
- Faculty of Medicine, Department of Radiation Oncology, Kocaeli University, Kocaeli, Turkey
| |
Collapse
|
2
|
Alfattah MA, Correia CN, Browne JA, McGettigan PA, Pluta K, Carrington SD, MacHugh DE, Irwin JA. Transcriptomics analysis of the bovine endometrium during the perioestrus period. PLoS One 2024; 19:e0301005. [PMID: 38547106 PMCID: PMC10977793 DOI: 10.1371/journal.pone.0301005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Accepted: 03/10/2024] [Indexed: 04/02/2024] Open
Abstract
During the oestrous cycle, the bovine endometrium undergoes morphological and functional changes, which are regulated by alterations in the levels of oestrogen and progesterone and consequent changes in gene expression. To clarify these changes before and after oestrus, RNA-seq was used to profile the transcriptome of oestrus-synchronized beef heifers. Endometrial samples were collected from 29 animals, which were slaughtered in six groups beginning 12 h after the withdrawal of intravaginal progesterone releasing devices until seven days post-oestrus onset (luteal phase). The groups represented proestrus, early oestrus, metoestrus and early dioestrus (luteal phase). Changes in gene expression were estimated relative to gene expression at oestrus. Ingenuity Pathway Analysis (IPA) was used to identify canonical pathways and functional processes of biological importance. A total of 5,845 differentially expressed genes (DEGs) were identified. The lowest number of DEGs was observed at the 12 h post-oestrus time point, whereas the greatest number was observed at Day 7 post-oestrus onset (luteal phase). A total of 2,748 DEGs at this time point did not overlap with any other time points. Prior to oestrus, Neurological disease and Organismal injury and abnormalities appeared among the top IPA diseases and functions categories, with upregulation of genes involved in neurogenesis. Lipid metabolism was upregulated before oestrus and downregulated at 48h post-oestrus, at which point an upregulation of immune-related pathways was observed. In contrast, in the luteal phase the Lipid metabolism and Small molecule biochemistry pathways were upregulated.
Collapse
Affiliation(s)
- Mohammed A. Alfattah
- UCD School of Veterinary Medicine, UCD College of Health and Agricultural Sciences, University College Dublin, Belfield, Dublin, Ireland
- King Faisal University, Al-Ahsa, Saudi Arabia
| | - Carolina N. Correia
- Animal Genomics Laboratory, UCD School of Agriculture and Food Science, UCD College of Health and Agricultural Sciences, University College Dublin, Belfield, Dublin, Ireland
| | - John A. Browne
- UCD School of Veterinary Medicine, UCD College of Health and Agricultural Sciences, University College Dublin, Belfield, Dublin, Ireland
| | - Paul A. McGettigan
- UCD School of Veterinary Medicine, UCD College of Health and Agricultural Sciences, University College Dublin, Belfield, Dublin, Ireland
| | - Katarzyna Pluta
- UCD School of Veterinary Medicine, UCD College of Health and Agricultural Sciences, University College Dublin, Belfield, Dublin, Ireland
| | - Stephen D. Carrington
- UCD School of Veterinary Medicine, UCD College of Health and Agricultural Sciences, University College Dublin, Belfield, Dublin, Ireland
| | - David E. MacHugh
- Animal Genomics Laboratory, UCD School of Agriculture and Food Science, UCD College of Health and Agricultural Sciences, University College Dublin, Belfield, Dublin, Ireland
- UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland
| | - Jane A. Irwin
- UCD School of Veterinary Medicine, UCD College of Health and Agricultural Sciences, University College Dublin, Belfield, Dublin, Ireland
| |
Collapse
|
3
|
Vasquez YM, Wu SP, Anderson ML, Hawkins SM, Creighton CJ, Ray M, Tsai SY, Tsai MJ, Lydon JP, DeMayo FJ. Endometrial Expression of Steroidogenic Factor 1 Promotes Cystic Glandular Morphogenesis. Mol Endocrinol 2016; 30:518-32. [PMID: 27018534 DOI: 10.1210/me.2015-1215] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Epigenetic silencing of steroidogenic factor 1 (SF1) is lost in endometriosis, potentially contributing to de novo local steroidogenesis favoring inflammation and growth of ectopic endometrial tissue. In this study, we examine the impact of SF1 expression in the eutopic uterus by a novel mouse model that conditionally expresses SF1 in endometrium. In vivo SF1 expression promoted the development of enlarged endometrial glands and attenuated estrogen and progesterone responsiveness. Endometriosis induction by autotransplantation of uterine tissue to the mesenteric membrane resulted in the increase in size of ectopic lesions from SF1-expressing mice. By integrating the SF1-dependent transcriptome with the whole genome binding profile of SF1, we identified uterine-specific SF1-regulated genes involved in Wingless and Progesterone receptor-Hedgehog-Chicken ovalbumin upstream promoter transcription factor II signaling for gland development and epithelium-stroma interaction, respectively. The present results indicate that SF1 directly contributes to the abnormal uterine gland morphogenesis, an inhibition of steroid hormone signaling and activation of an immune response, in addition to previously postulated estrogen production.
Collapse
Affiliation(s)
- Yasmin M Vasquez
- Department of Molecular and Cellular Biology (Y.M.V., S.Y.T., M.-J.T., J.P.L., F.J.D.), Baylor College of Medicine, Houston, Texas 77030; Department of Obstetrics and Gynecology (M.L.A., S.M.H.), Baylor College of Medicine, Houston, Texas 77030; Dan L. Duncan Cancer Center (M.L.A., C.J.C.), Division of Biostatistics, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030; and Pregnancy and Female Reproduction Group (S.-P.W., M.R., M.J.D.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
| | - San-Pin Wu
- Department of Molecular and Cellular Biology (Y.M.V., S.Y.T., M.-J.T., J.P.L., F.J.D.), Baylor College of Medicine, Houston, Texas 77030; Department of Obstetrics and Gynecology (M.L.A., S.M.H.), Baylor College of Medicine, Houston, Texas 77030; Dan L. Duncan Cancer Center (M.L.A., C.J.C.), Division of Biostatistics, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030; and Pregnancy and Female Reproduction Group (S.-P.W., M.R., M.J.D.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
| | - Matthew L Anderson
- Department of Molecular and Cellular Biology (Y.M.V., S.Y.T., M.-J.T., J.P.L., F.J.D.), Baylor College of Medicine, Houston, Texas 77030; Department of Obstetrics and Gynecology (M.L.A., S.M.H.), Baylor College of Medicine, Houston, Texas 77030; Dan L. Duncan Cancer Center (M.L.A., C.J.C.), Division of Biostatistics, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030; and Pregnancy and Female Reproduction Group (S.-P.W., M.R., M.J.D.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
| | - Shannon M Hawkins
- Department of Molecular and Cellular Biology (Y.M.V., S.Y.T., M.-J.T., J.P.L., F.J.D.), Baylor College of Medicine, Houston, Texas 77030; Department of Obstetrics and Gynecology (M.L.A., S.M.H.), Baylor College of Medicine, Houston, Texas 77030; Dan L. Duncan Cancer Center (M.L.A., C.J.C.), Division of Biostatistics, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030; and Pregnancy and Female Reproduction Group (S.-P.W., M.R., M.J.D.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
| | - Chad J Creighton
- Department of Molecular and Cellular Biology (Y.M.V., S.Y.T., M.-J.T., J.P.L., F.J.D.), Baylor College of Medicine, Houston, Texas 77030; Department of Obstetrics and Gynecology (M.L.A., S.M.H.), Baylor College of Medicine, Houston, Texas 77030; Dan L. Duncan Cancer Center (M.L.A., C.J.C.), Division of Biostatistics, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030; and Pregnancy and Female Reproduction Group (S.-P.W., M.R., M.J.D.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
| | - Madhumita Ray
- Department of Molecular and Cellular Biology (Y.M.V., S.Y.T., M.-J.T., J.P.L., F.J.D.), Baylor College of Medicine, Houston, Texas 77030; Department of Obstetrics and Gynecology (M.L.A., S.M.H.), Baylor College of Medicine, Houston, Texas 77030; Dan L. Duncan Cancer Center (M.L.A., C.J.C.), Division of Biostatistics, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030; and Pregnancy and Female Reproduction Group (S.-P.W., M.R., M.J.D.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
| | - Sophia Y Tsai
- Department of Molecular and Cellular Biology (Y.M.V., S.Y.T., M.-J.T., J.P.L., F.J.D.), Baylor College of Medicine, Houston, Texas 77030; Department of Obstetrics and Gynecology (M.L.A., S.M.H.), Baylor College of Medicine, Houston, Texas 77030; Dan L. Duncan Cancer Center (M.L.A., C.J.C.), Division of Biostatistics, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030; and Pregnancy and Female Reproduction Group (S.-P.W., M.R., M.J.D.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
| | - Ming-Jer Tsai
- Department of Molecular and Cellular Biology (Y.M.V., S.Y.T., M.-J.T., J.P.L., F.J.D.), Baylor College of Medicine, Houston, Texas 77030; Department of Obstetrics and Gynecology (M.L.A., S.M.H.), Baylor College of Medicine, Houston, Texas 77030; Dan L. Duncan Cancer Center (M.L.A., C.J.C.), Division of Biostatistics, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030; and Pregnancy and Female Reproduction Group (S.-P.W., M.R., M.J.D.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
| | - John P Lydon
- Department of Molecular and Cellular Biology (Y.M.V., S.Y.T., M.-J.T., J.P.L., F.J.D.), Baylor College of Medicine, Houston, Texas 77030; Department of Obstetrics and Gynecology (M.L.A., S.M.H.), Baylor College of Medicine, Houston, Texas 77030; Dan L. Duncan Cancer Center (M.L.A., C.J.C.), Division of Biostatistics, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030; and Pregnancy and Female Reproduction Group (S.-P.W., M.R., M.J.D.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
| | - Francesco J DeMayo
- Department of Molecular and Cellular Biology (Y.M.V., S.Y.T., M.-J.T., J.P.L., F.J.D.), Baylor College of Medicine, Houston, Texas 77030; Department of Obstetrics and Gynecology (M.L.A., S.M.H.), Baylor College of Medicine, Houston, Texas 77030; Dan L. Duncan Cancer Center (M.L.A., C.J.C.), Division of Biostatistics, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030; and Pregnancy and Female Reproduction Group (S.-P.W., M.R., M.J.D.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
| |
Collapse
|
4
|
Jones A, Teschendorff AE, Li Q, Hayward JD, Kannan A, Mould T, West J, Zikan M, Cibula D, Fiegl H, Lee SH, Wik E, Hadwin R, Arora R, Lemech C, Turunen H, Pakarinen P, Jacobs IJ, Salvesen HB, Bagchi MK, Bagchi IC, Widschwendter M. Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med 2013; 10:e1001551. [PMID: 24265601 PMCID: PMC3825654 DOI: 10.1371/journal.pmed.1001551] [Citation(s) in RCA: 112] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2013] [Accepted: 10/03/2013] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND Endometrial cancer incidence is continuing to rise in the wake of the current ageing and obesity epidemics. Much of the risk for endometrial cancer development is influenced by the environment and lifestyle. Accumulating evidence suggests that the epigenome serves as the interface between the genome and the environment and that hypermethylation of stem cell polycomb group target genes is an epigenetic hallmark of cancer. The objective of this study was to determine the functional role of epigenetic factors in endometrial cancer development. METHODS AND FINDINGS Epigenome-wide methylation analysis of >27,000 CpG sites in endometrial cancer tissue samples (n = 64) and control samples (n = 23) revealed that HAND2 (a gene encoding a transcription factor expressed in the endometrial stroma) is one of the most commonly hypermethylated and silenced genes in endometrial cancer. A novel integrative epigenome-transcriptome-interactome analysis further revealed that HAND2 is the hub of the most highly ranked differential methylation hotspot in endometrial cancer. These findings were validated using candidate gene methylation analysis in multiple clinical sample sets of tissue samples from a total of 272 additional women. Increased HAND2 methylation was a feature of premalignant endometrial lesions and was seen to parallel a decrease in RNA and protein levels. Furthermore, women with high endometrial HAND2 methylation in their premalignant lesions were less likely to respond to progesterone treatment. HAND2 methylation analysis of endometrial secretions collected using high vaginal swabs taken from women with postmenopausal bleeding specifically identified those patients with early stage endometrial cancer with both high sensitivity and high specificity (receiver operating characteristics area under the curve = 0.91 for stage 1A and 0.97 for higher than stage 1A). Finally, mice harbouring a Hand2 knock-out specifically in their endometrium were shown to develop precancerous endometrial lesions with increasing age, and these lesions also demonstrated a lack of PTEN expression. CONCLUSIONS HAND2 methylation is a common and crucial molecular alteration in endometrial cancer that could potentially be employed as a biomarker for early detection of endometrial cancer and as a predictor of treatment response. The true clinical utility of HAND2 DNA methylation, however, requires further validation in prospective studies. Please see later in the article for the Editors' Summary.
Collapse
Affiliation(s)
- Allison Jones
- Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, United Kingdom
| | - Andrew E. Teschendorff
- Statistical Cancer Genomics, UCL Cancer Institute, University College London, London, United Kingdom
- CAS-MPG Partner Institute for Computational Biology, Chinese Academy of Sciences, Shanghai Institute for Biological Sciences, Shanghai, China
| | - Quanxi Li
- Department of Comparative Biosciences, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America
| | - Jane D. Hayward
- Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, United Kingdom
| | - Athilakshmi Kannan
- Department of Comparative Biosciences, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America
| | - Tim Mould
- Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, United Kingdom
| | - James West
- Statistical Cancer Genomics, UCL Cancer Institute, University College London, London, United Kingdom
- Centre for Mathematics and Physics in the Life Sciences and Experimental Biology, University College London, London, United Kingdom
| | - Michal Zikan
- Gynaecologic Oncology Center, Department of Obstetrics and Gynaecology, First Faculty of Medicine and General University Hospital, Charles University Prague, Prague, Czech Republic
| | - David Cibula
- Gynaecologic Oncology Center, Department of Obstetrics and Gynaecology, First Faculty of Medicine and General University Hospital, Charles University Prague, Prague, Czech Republic
| | - Heidi Fiegl
- Department of Gynaecology and Obstetrics, Innsbruck Medical University, Innsbruck, Austria
| | - Shih-Han Lee
- Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, United Kingdom
| | - Elisabeth Wik
- Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway
- Center for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Richard Hadwin
- Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, United Kingdom
| | - Rupali Arora
- Department of Pathology, UCL Cancer Institute, University College London, London, United Kingdom
| | - Charlotte Lemech
- Department of Medical Oncology, UCL Cancer Institute, University College London, London, United Kingdom
| | - Henna Turunen
- Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Finland
| | - Päivi Pakarinen
- Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Finland
| | - Ian J. Jacobs
- Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, United Kingdom
- Faculty of Medical and Human Sciences, University of Manchester, Manchester, United Kingdom
| | - Helga B. Salvesen
- Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway
- Center for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Milan K. Bagchi
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America
| | - Indrani C. Bagchi
- Department of Comparative Biosciences, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America
| | - Martin Widschwendter
- Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, United Kingdom
- * E-mail:
| |
Collapse
|